Fetal antipsychotic exposure in a changing landscape: Seeing the future

British Journal of Psychiatry

Volumn 202, Issue 5, 2013, Pages 321-323

  Abel, Kathryn M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; FOLIC ACID; HALOPERIDOL; NEUROLEPTIC AGENT; PENFLURIDOL; SERTINDOLE; ZOTEPINE;

CONGENITAL MALFORMATION; DISEASE ASSOCIATION; EXTRAPYRAMIDAL SYNDROME; FOLIC ACID BLOOD LEVEL; HUMAN; LARGE FOR GESTATIONAL AGE; MATERNAL SMOKING; MEDICAL DECISION MAKING; MONOTHERAPY; MORNING SICKNESS; OBESITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PERINATAL DRUG EXPOSURE; PHARMACOEPIDEMIOLOGY; PREGNANCY OUTCOME; REVIEW; RISK ASSESSMENT; SMALL FOR DATE INFANT; VITAMIN INTAKE;

ABNORMALITIES, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; COHORT EFFECT; DEVELOPMENTAL DISABILITIES; FEMALE; FORECASTING; HUMANS; MATERNAL EXPOSURE; MEDICATION ADHERENCE; MENTAL DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PRENATAL EXPOSURE DELAYED EFFECTS; RISK FACTORS;

EID: 84877586399     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.112.117556     Document Type: Review

References (14)

1. McKenna K, Koren G, Tetelbaum M, Wilton L, Shakir S, Diav-Citrin O, et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry 2005; 66: 444-9. (Pubitemid 40593572)
2. Webb RT, Howard L, Abel KM. Antipsychotic drugs for non-affective psychosis during pregnancy and postpartum. Cochrane Database Syst Rev 2004; 2: CD004411.
3. National Institute for Health and Clinical Excellence. Antenatal and Postnatal Mental Health. Clinical Guideline 45. NICE, 2007.
4. Barnes TR. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2011; 25: 567-620.
5. Webb RT, Pickles AR, King-Hele SA, Appleby L, Mortensen PB, Abel KM. Parental mental illness and fatal birth defects in a national birth cohort. Psychol Med 2008; 38: 1495-503.
6. Altshuler LL, Cohen L, Szuba MP, Burt VK, Gitlin M, Mintz J. Pharmacological management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996; 153: 592-606. (Pubitemid 26133611)
7. Reis M, Kallen B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol 2008; 28: 279-88.
8. Gentile S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull 2010; 36: 518-44.
9. Bodén R, Lundgren M, Brandt L, Reutfors J, Kieler H. Antipsychotics during pregnancy: relation to fetal and maternal metabolic effects. Arch Gen Psychiatry 2012; 69: 715-21.
10. Lin HC, Chen IJ, Chen YH, Lee HC, Wu FJ. Maternal schizophrenia and pregnancy outcome: does the use of antipsychotics make a difference? Schizophr Res 2010; 116: 55-60.
11. Abel KM, Morgan VA. Mental illness, women, mothers, and their children. In Textbook in Psychiatric Epidemiology (3rd edn) (eds MT Tsaug, M Tohen, P Jones): 483-514. Wiley-Blackwell, 2011.
12. Bodén R, Lundgren M, Brandt L, Reutfors J, Andersen M, Kieler H. Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study. BMJ 2012; 345: e7085.
13. The Health and Social Care Information Centre. Prescription Cost Analysis: England 2010. The Health and Social Care Information Centre, 2011.
14. Newport DJ, Calamaras MR, DeVane CL, Donovan J, Beach AJ, Winn S, et al. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry 2007; 164: 1214-20. (Pubitemid 47292410)